Document is current
Any future updates will be listed below
-
Authors
Zakrzewska, Sandra https://orcid.org/0000-0002-8706-4394
Nixon, Samantha A. https://orcid.org/0000-0003-3157-4114
Chen, Zhou https://orcid.org/0000-0002-4426-2497
Hajare, Holly S.
Park, Elizabeth R. https://orcid.org/0000-0001-9974-3899
Mulcahy, John V. https://orcid.org/0000-0002-3997-6073
Arlinghaus, Kandis M.
Neu, Eduard https://orcid.org/0000-0003-2999-1488
Konovalov, Kirill
Provasi, Davide
Leighfield, Tod A.
Filizola, Marta https://orcid.org/0000-0002-4382-8276
Du Bois, J. https://orcid.org/0000-0001-7847-1548
Minor, Daniel L. Jr. https://orcid.org/0000-0002-5998-4214
-
Funding
Funding for this research was provided by:
United States Department of Defense | Defense Threat Reduction Agency (HDTRA-1-19-1-0040, HDTRA 1 21-1-0011, HDTRA-1-23-1-0026)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01 GM117263 05)
Studienstiftung des Deutschen Volkes
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR004419)
- License Information
-
More Information
Article History
Received: 14 November 2024
Accepted: 4 April 2025
First Online: 24 April 2025
Competing interests
: J.D. is a cofounder and holds equity shares in SiteOne Therapeutics, Inc., a start-up company interested in developing subtype-selective modulators of sodium channels. The scientific results and conclusions, as well as any views or opinions expressed herein, are those of the authors and do not necessarily reflect the policies and views of the Department of Commerce (DOC), NOAA, DOE, or ORAU/ORISE. The other authors declare no competing interests.
